All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Latest GRAPPA guidelines for treatment of PsA Abs#OP0229 #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8
Robert B Chao, MD doctorRBC ( View Tweet)
Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Robert B Chao, MD doctorRBC ( View Tweet)
Key points on phenotypes in PsA per Dr. Dafna Gladman: ⭐️Oligoarticular & polyarticular PsA pts have the same burden of dz ⭐️Dactylitis assoc w/ greater dz severity & US synovitis + erosive changes in DMARD-naive early PsA pts #EULAR2021 @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#EULAR2021 Gender differences in chronic #arthritis 🙋🙋‍♂️ ▶️ POS1061: The Italian prospective SIRENA study: women do worse at the onset of #psoriaticarthritis 🇮🇹 ▶️ POS0208: The Austrian Registry BIOREG: women showed lower response rates to #TNFi 🇦🇹 > LA https://t.co/JNxrqimp2Y
ARD & RMD Open ARD_BMJ ( View Tweet)
Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Richard Conway RichardPAConway ( View Tweet)
Israeli study of all cause mortality in PsA vs general population ⭐️no increased mortality in PsA group ⭐️leading causes of death was cancer in both groups ⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs Abs#OP0219 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well.. It’s time for more personalized approach to PsA treatment! Excellent talk by @DrLauraCoates Abs#OP6937 #EULAR2021 @RheumNow https://t.co/1NKLfmH2y5
Robert B Chao, MD doctorRBC ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl
Robert B Chao, MD doctorRBC ( View Tweet)
#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE
Paul Studenic Stiddyo ( View Tweet)
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Paul Studenic Stiddyo ( View Tweet)
Several domains of disease in #PsA need to be considered. Composite scores have the benefit of providing a summary. What is your favourite composite score for PsA in your clinical practice? #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×